RESOLVING THE LEDGER
This is one outlet's own report from Scientific American — the article as it was filed. Other outlets are covering the same event; open the full story to compare every source side by side.
See the full story · 4 sources
Estrogen-only hormone therapy could lower risk of Alzheimer's
In a retrospective study, people taking estrogen-only hormone therapy for menopause were less likely to see signs of dementia
Alzheimer's disease disproportionately affects women—around two thirds of the people who develop it are female. Why that is the case isn't totally clear . It may be because women tend to live longer than men or perhaps because of social or genetic factors. But emerging research points to another potential risk factor: menopause.
During menopause , the ovaries stop producing mature eggs, and the production of estrogen, a sex hormone critical to female reproductive health, slows. Research hints that this precipitous drop in estrogen may affect how our brains age.
"One of the prevailing hypotheses is that this sharp decline in estrogen may somehow contribute to differences in brain aging," including the likelihood of developing Alzheimer's, says Jennifer Bruno, a cognitive neuroscientist at Stanford University.
If you're enjoying this article, consider supporting our award-winning journalism by subscribing . By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Now a new study by Bruno and her colleagues that was published in Neurology on Wednesday provides another clue to the possible link between menopause and dementia.
The researchers analyzed two datasets that included a total of 21,462 patient records; for one of the datasets, nearly 3,000 people had donated their brains for science when they died. Overall, patients who took estrogen-only hormone therapy for menopause were less likely to display signs of memory loss or cognitive decline or to be diagnosed with dementia.
In the nearly 3,000 patients who donated their brains to science, the brains of those who took estrogen were less likely to show neurobiological hallmarks of Alzheimer's disease, such as beta-amyloid plaques or tangles of tau protein. The researchers accounted for confounding factors such as age, race, history of hypertension and other traits, notes Jacob Shaw, a study co-author and psychiatry resident at Massachusetts General Hospital/McLean Hospital. The other dataset also showed a drop in Alzheimer's-related biomarkers in living patients who took estrogen.
Importantly, the study surfaces an association between estrogen-only hormone therapy and a lower risk of dementia—it doesn't prove that estrogen-only therapy prevents or treats dementia.
There may be other factors at play, says Hadi Hosseini, a neuroscientist at Stanford University and the study's senior author. It could be that women who took estrogen-only hormone therapy were healthier overall than those who did not or had better access to health care, or something else could have been involved, he says.
Another limitation is that the research team didn't have access to information about why each of the patients had been taking estrogen-only therapy. Because it is associated with an increased risk of endometrial cancer, estrogen-only therapy is primarily recommended for menopause treatment in women who have undergone hysterectomies, but the datasets in this study didn't include hysterectomy records.
Another complication is that some past research suggests that other hormonal therapies, including a combination of the sex hormone progesterone and estrogen, may be associated with a higher risk of dementia. It's not totally clear why.
More research into the relationship between menopause, estrogen and dementia—including long-term studies that track patients as they age—is needed, the authors say. "It sets the stage for the future randomized controlled trials," Bruno says.
Jackie Flynn Mogensen is a breaking news reporter at Scientific American . Before joining SciAm, she was a science reporter at Mother Jones, where she received a National Academies Eric and Wendy Schmidt Award for Excellence in Science Communications in 2024. Mogensen holds a master's degree in environmental communication and a bachelor's degree in earth sciences from Stanford University. She is based in New York City.
If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.
SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.
If you subscribe to Scientific American , you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.
There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.
Jeanna Bryner, Editor in Chief, Scientific American
AIPROPX is an independent multi-source news index — we track, compare, and connect coverage from across the web into one place you won't find anywhere else.